Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials - 26/09/12
, Sara M Debanne, PhD b, Douglas Y Rowland, PhD b, Daniel I Simon, MD a, James C Fang, MD aSummary |
Background |
Angiotensin-receptor blockers (ARBs) are a widely used drug class approved for treatment of hypertension, heart failure, diabetic nephropathy, and, recently, for cardiovascular risk reduction. Experimental studies implicate the renin-angiotensin system, particularly angiotensin II type-1 and type-2 receptors, in the regulation of cell proliferation, angiogenesis, and tumour progression. We assessed whether ARBs affect cancer occurrence with a meta-analysis of randomised controlled trials of these drugs.
Methods |
We searched Medline, Scopus (including Embase), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the US Food and Drug Administration website for studies published before November, 2009, that included any of the seven currently available ARBs. Randomised controlled trials with an ARB given in at least one group, with a follow-up of at least 1 year, and that enrolled at least 100 patients were included. New-cancer data were available for 61
590 patients from five trials. Data on common types of solid organ cancers were available for 68402 patients from five trials, and data on cancer deaths were available for 93515 patients from eight trials.
Findings |
Telmisartan was the study drug in 30014 (85·7%) patients who received ARBs as part of the trials with new cancer data. Patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7·2% vs 6·0%, risk ratio [RR] 1·08, 95% CI 1·01–1·15; p=0·016). When analysis was limited to trials where cancer was a prespecified endpoint, the RR was 1·11 (95% CI 1·04–1·18, p=0·001). Among specific solid organ cancers examined, only new lung-cancer occurrence was significantly higher in patients randomly assigned to receive ARBs than in those assigned to receive control (0·9% vs 0·7%, RR 1·25, 1·05–1·49; p=0·01). No statistically significant difference in cancer deaths was observed (1·8% vs 1·6%, RR 1·07, 0·97–1·18; p=0·183).
Interpretation |
This meta-analysis of randomised controlled trials suggests that ARBs are associated with a modestly increased risk of new cancer diagnosis. Given the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each particular drug. These findings warrant further investigation.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 11 - N° 7
P. 627-636 - juillet 2010 Retour au numéro
Article précédent
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma, John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada, Bruce E Johnson
- Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial
- Sung-Bum Kang, Ji Won Park, Seung-Yong Jeong, Byung Ho Nam, Hyo Seong Choi, Duck-Woo Kim, Seok-Byung Lim, Taek-Gu Lee, Dae Yong Kim, Jae-Sung Kim, Hee Jin Chang, Hye-Seung Lee, Sun Young Kim, Kyung Hae Jung, Yong Sang Hong, Jee Hyun Kim, Dae Kyung Sohn, Dae-Hyun Kim, Jae Hwan Oh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?